These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 17038906

  • 1. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.
    Uzunel M, Remberger M, Sairafi D, Hassan Z, Mattsson J, Omazic B, Barkholt L, Ringdén O.
    Transplantation; 2006 Oct 15; 82(7):913-9. PubMed ID: 17038906
    [Abstract] [Full Text] [Related]

  • 2. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
    Faber E, Koza V, Vitek A, Mayer J, Sedlacek P, Zak P, Zapletalova J, Benesova K, Krejcova H, Steinerova K, Maresova I, Cetkovsky P, Czech National Hematopoietic Stem Cell Transplantation Registry.
    Neoplasma; 2007 Oct 15; 54(5):443-6. PubMed ID: 17688375
    [Abstract] [Full Text] [Related]

  • 3. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander AR.
    Exp Hematol; 2008 Aug 15; 36(8):1047-54. PubMed ID: 18456390
    [Abstract] [Full Text] [Related]

  • 4. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
    Banna GL, Aversa S, Sileni VC, Favaretto A, Ghiotto C, Monfardini S.
    Crit Rev Oncol Hematol; 2004 Sep 15; 51(3):171-89. PubMed ID: 15331077
    [Abstract] [Full Text] [Related]

  • 5. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan.
    Yanada M, Emi N, Naoe T, Sakamaki H, Takahashi S, Hirabayashi N, Hiraoka A, Kanda Y, Tanosaki R, Okamoto S, Iwato K, Atsuta Y, Hamajima N, Tanimoto M, Kato S.
    Bone Marrow Transplant; 2004 Aug 15; 34(4):331-7. PubMed ID: 15220958
    [Abstract] [Full Text] [Related]

  • 6. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF.
    Br J Haematol; 2005 Aug 15; 130(3):394-403. PubMed ID: 16042689
    [Abstract] [Full Text] [Related]

  • 7. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D, Martino R, Sureda A, Canals C, Altés A, Briones J, Sanz MA, Parody R, Constans M, Villela SL, Brunet S, Sierra J.
    Eur J Haematol; 2005 Feb 15; 74(2):144-51. PubMed ID: 15654906
    [Abstract] [Full Text] [Related]

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 15; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 9. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients.
    Kim HJ, Park CY, Park YH, Kim YJ, Kim DW, Min WS, Kim CC.
    Bone Marrow Transplant; 2003 Jan 15; 31(2):79-86. PubMed ID: 12621487
    [Abstract] [Full Text] [Related]

  • 10. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE, Kambouris ME, Sinfield L, Lange J, Burns AM, Lourie R, Atkinson K, Hart DN, Munster DJ, Rice AM.
    Transplantation; 2008 Oct 15; 86(7):968-76. PubMed ID: 18852664
    [Abstract] [Full Text] [Related]

  • 11. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
    Bacigalupo A, Sormani MP, Lamparelli T, Gualandi F, Occhini D, Bregante S, Raiola AM, di Grazia C, Dominietto A, Tedone E, Piaggio G, Podesta M, Bruno B, Oneto R, Lombardi A, Frassoni F, Rolla D, Rollandi G, Viscoli C, Ferro C, Garbarino L, Van Lint MT.
    Haematologica; 2004 Oct 15; 89(10):1238-47. PubMed ID: 15477210
    [Abstract] [Full Text] [Related]

  • 12. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
    Hartwig UF, Winkelmann N, Wehler T, Kreiter S, Schneider PM, Meyer RG, Ullmann AJ, Huber C, Kolbe K, Herr W.
    Ann Hematol; 2005 May 15; 84(5):331-8. PubMed ID: 15726363
    [Abstract] [Full Text] [Related]

  • 13. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies.
    Corradini P, Zallio F, Mariotti J, Farina L, Bregni M, Valagussa P, Ciceri F, Bacigalupo A, Dodero A, Lucesole M, Patriarca F, Rambaldi A, Scimè R, Locasciulli A, Bandini G, Gianni AM, Tarella C, Olivieri A.
    J Clin Oncol; 2005 Sep 20; 23(27):6690-8. PubMed ID: 16170177
    [Abstract] [Full Text] [Related]

  • 14. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S.
    Blood Cells Mol Dis; 2008 Sep 20; 40(1):48-54. PubMed ID: 17827036
    [Abstract] [Full Text] [Related]

  • 15. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C, Meijer E, Petersen EJ, Lokhorst HM, Verdonck LF.
    Biol Blood Marrow Transplant; 2008 Feb 20; 14(2):181-6. PubMed ID: 18215778
    [Abstract] [Full Text] [Related]

  • 16. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R, Enczmann J, Balzer S, Bernbeck B, Kramm C, Schönberger S, Sinha K, Tröger A, Wernet P, Göbel U, Laws HJ, Dilloo D.
    Klin Padiatr; 2005 Feb 20; 217(3):135-41. PubMed ID: 15858704
    [Abstract] [Full Text] [Related]

  • 17. Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine.
    Görner M, Kordelas L, Thalheimer M, Luft T, Pfeiffer S, Ustaoglu F, Punzel M, Weber-Nordt R, Moos M, Goldschmidt H, Ho AD.
    Bone Marrow Transplant; 2002 Apr 20; 29(7):621-4. PubMed ID: 11979314
    [Abstract] [Full Text] [Related]

  • 18. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
    Nachbaur D, Larcher C, Kircher B, Eibl G, Nussbaumer W, Gunsilius E, Haun M, Grünewald K, Gastl G.
    Ann Hematol; 2003 Oct 20; 82(10):621-7. PubMed ID: 12920570
    [Abstract] [Full Text] [Related]

  • 19. Unrelated donor transplantation after reduced intensity conditioning as an approach for patients lacking related donors for allogeneic stem cell transplantation.
    Hoepfner S, Goerner M, Benner A, Henning P, Ho AD.
    J Hematother Stem Cell Res; 2003 Jun 20; 12(3):331-9. PubMed ID: 12857374
    [Abstract] [Full Text] [Related]

  • 20. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N, Chang K, Slovak ML, Bhatia R, Spielberger R, Kogut N, Pullarkat V, Kirschbaum M, Forman SJ, O'Donnell MR.
    Bone Marrow Transplant; 2007 Nov 20; 40(9):843-50. PubMed ID: 17724447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.